Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 478150
Wayne Rooney  |  by www.tradingmarkets.com. All rights reserved. 13.11 | 23:23

Receive Dave's best setups each evening from his favorite trading patterns.

Let Gary Kaltbaum send you timely emails to alrt when breakouts occure.
Every day receive the best plan of attack for the next day's trading directly from professional trader Kevin Haggerty.

(RTTNews) - Monday evening, pharmaceutical company Alpharma Inc. ( | | | ) said it received United States Food and Drug Administration or FDA's approval for its KADIAN 80mg capsules. The company stated that it expects to launch the new dosage strength in the fourth quarter of 2006.

According to the Fort Lee, New Jersey-based company, KADIAN is its branded sustained release morphine sulfate product. The drug is currently available in the market in 20mg, 30mg, 50mg, 60mg and 100mg dosages. The added dosage is expected to assist in physician's efforts to individualize the patient's treatments by offering more choices in managing the pain, Alpharma added.

Alpharma noted that it has conducted in vivo studies to evaluate the interaction of alcohol consumption with KADIAN. The results indicated that the concomitant use of tested levels of alcohol with KADIAN has no significant impact on mean morphine blood levels. The company provided this data to the FDA and any future labeling implications would be determined following the completion of this review, Alpharma added.

ALO closed Monday's regular trading session at $22.30, up $0.43 or 1.

97%, on a volume of 572K shares.

Read more on by www.tradingmarkets.com. All rights reserved.
Related news
Post comments
Name
Place
2 + 3 =
Comments